Creative Medical Technology Holdings (CELZ) Price to Earnings (2016 - 2026)
Creative Medical Technology Holdings' (CELZ) quarterly Price to Earnings came in at 1.28 in Q2 2026, up 55.35% year-over-year from 0.82 in Q2 2025, and up 34.62% quarter-over-quarter from 1.95 in Q1 2026.
Powered by 
Analysis
Creative Medical Technology Holdings (CELZ) Price to Earnings (2016 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Price to Earnings for 11 consecutive years, with 1.28 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Price to Earnings rose 55.35% year-over-year to 1.28 in Q2 2026; TTM through Jun 2026 was 0.27, a 48.16% increase from a year earlier, with the FY2025 full-year figure at 0.37, up 22.33% from the prior year.
- Price to Earnings was 1.28 for Q2 2026 at Creative Medical Technology Holdings, up from 1.95 in the prior quarter.
- Over five years, Price to Earnings peaked at 0.67 in Q4 2022 and troughed at 22.02 in Q1 2022.
- A 5-year average of 4.52 and a median of 3.68 in 2023 frame the typical range for Price to Earnings.
- Across the five-year window, Price to Earnings plunged 1724.02% in 2022 and surged 74.0% in 2025, its largest moves.
- Over 5 years, Price to Earnings stood at 0.67 in 2022, then plunged by 462.83% to 3.77 in 2023, then soared by 72.64% to 1.03 in 2024, then advanced by 19.05% to 0.84 in 2025, then slumped by 52.73% to 1.28 in 2026.
- The last three Price to Earnings figures came in at 1.28 (Q2 2026), 1.95 (Q1 2026), and 0.84 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Creative Medical Technology Holdings | 1.45 Mn | 1.45 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.28 |
| Mar 31, 2026 | -1.95 |
| Dec 31, 2025 | -0.84 |
| Sep 30, 2025 | -3.58 |
| Jun 30, 2025 | -2.86 |
| Mar 31, 2025 | -1.76 |
| Dec 31, 2024 | -1.03 |
| Sep 30, 2024 | -3.96 |
| Jun 30, 2024 | -3.31 |
| Mar 31, 2024 | -6.78 |
| Dec 31, 2023 | -3.77 |
| Sep 30, 2023 | -4.71 |
| Jun 30, 2023 | -6.02 |
| Mar 31, 2023 | -6.69 |
| Dec 31, 2022 | -0.67 |
| Sep 30, 2022 | -6.30 |
| Jun 30, 2022 | -3.77 |
| Mar 31, 2022 | -22.02 |
| Dec 31, 2021 | -1.49 |
| Sep 30, 2021 | -9.98 |